SEC Form 4 · accession 0001209191-15-081510
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Altshuler
Officer — EVP, Global Research and CSO
Period of report
Nov 18, 2015
Accepted (ET)
Nov 20, 2015 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 18, 2015 | M | 7,500 | $72.14 | A | 82,500 | D | |
| Common Stock | Nov 18, 2015 | M | 7,500 | $63.14 | A | 90,000 | D | |
| Common Stock | Nov 18, 2015 | S | 15,000 | $130.00 | D | 75,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $72.14 | Nov 18, 2015 | M | 7,500 | D | — | May 31, 2024 | Common Stock | 7,500 | 12,500 | D |
| Stock Option (right to buy)F3 | $63.14 | Nov 18, 2015 | M | 7,500 | D | — | May 23, 2022 | Common Stock | 7,500 | 7,500 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
- F2Fully vested.
- F3The option vests in 16 quarterly installments from 05/24/2012.